SEC Company Response from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Sep 21, 2018

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Sept. 21, 2018 · CIK: 0001137883 · Accession: 0001144204-18-050408

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-225995

Date

September 21, 2018

Author

Chaim Lebovits

Form

CORRESP

Company

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)

Letter

BRAINSTORM CELL THERAPEUTICS INC.

1325 Avenue of Americas 28th Floor

New York, NY 10019

September 21, 2018

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Christine Westbrook

RE:

Brainstorm Cell Therapeutics Inc.

Registration Statement on Form S-3

Filed June 29, 2018

File No. 333-225995

Acceleration Request

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the “Company”) hereby respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday, September 28, 2018, at 5:00 p.m. Eastern Time, or as soon as practicable thereafter.

Any questions regarding this request should be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.

Very truly yours,
Brainstorm Cell Therapeutics Inc.

Show Raw Text

CORRESP
1
filename1.htm

BRAINSTORM CELL THERAPEUTICS INC.

1325 Avenue of Americas 28th Floor

New York, NY 10019

    September 21, 2018

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C.  20549

Attention: Christine Westbrook

    RE:

        Brainstorm Cell Therapeutics Inc.

        Registration Statement on Form S-3

        Filed June 29, 2018

        File No. 333-225995

        Acceleration Request

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations
promulgated under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the “Company”) hereby
respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday,
September 28, 2018, at 5:00 p.m. Eastern Time, or as soon as practicable thereafter.

Any questions regarding this request should
be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.

        Very truly yours,

        Brainstorm Cell Therapeutics Inc.

            /s/ Chaim Lebovits

        By: Chaim Lebovits

        Its:  President and Chief Executive Officer

 cc: Thomas B. Rosedale, Esq.

(BRL
Law Group LLC)

SecProbe.io